Clarus Therapeutics (NASDAQ:CRXT – Get Rating) and SOPHiA GENETICS (NASDAQ:SOPH – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability. Analyst Ratings This is a summary of current ratings […]
Clarus Therapeutics (NASDAQ:CRXT – Get Rating) had its target price reduced by analysts at Maxim Group to $1.50 in a note issued to investors on Thursday, Stock Target Advisor reports. Maxim Group’s price target suggests a potential upside of 284.52% from the stock’s current price. Several other analysts have also recently issued reports on the […]
Clarus Therapeutics (NASDAQ:CRXT – Get Rating) had its target price decreased by stock analysts at Truist Financial from $7.00 to $3.00 in a research report issued to clients and investors on Tuesday, The Fly reports. Truist Financial’s target price indicates a potential upside of 458.24% from the stock’s previous close. Other research analysts have also […]
Analysts expect Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT – Get Rating) to announce ($0.86) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Clarus Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.13) and the highest estimate coming in at ($0.59). The business is […]
Analysts expect Clarus Therapeutics Holdings Inc (NASDAQ:CRXT – Get Rating) to report earnings of ($0.86) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Clarus Therapeutics’ earnings. The highest EPS estimate is ($0.59) and the lowest is ($1.13). The firm is scheduled to report its next earnings […]